<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34576165</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>18</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Passive Transfer of Blood Sera from ALS Patients with Identified Mutations Results in Elevated Motoneuronal Calcium Level and Loss of Motor Neurons in the Spinal Cord of Mice.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">9994</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms22189994</ELocationID><Abstract><AbstractText><b>Introduction:</b> Previously, we demonstrated the degeneration of axon terminals in mice after repeated injections of blood sera from amyotrophic lateral sclerosis (ALS) patients with identified mutations. However, whether a similar treatment affects the cell body of motor neurons (MNs) remained unresolved. <b>Methods:</b> Sera from healthy individuals or ALS patients with a mutation in different ALS-related genes were intraperitoneally injected into ten-week-old male Balb/c mice (<i>n</i> = 3/serum) for two days. Afterward, the perikaryal calcium level was measured using electron microscopy. Furthermore, the optical disector method was used to evaluate the number of lumbar MNs. <b>Results:</b> The cytoplasmic calcium level of the lumbar MNs of the ALS-serum-treated mice, compared to untreated and healthy-serum-treated controls, was significantly elevated. While injections of the healthy serum did not reduce the number of MNs compared to the untreated control group, ALS sera induced a remarkable loss of MNs. <b>Discussion:</b> Similarly to the distant motor axon terminals, the injection of blood sera of ALS patients has a rapid degenerative effect on MNs. Analogously, the magnitude of the evoked changes was specific to the type of mutation; furthermore, the degeneration was most pronounced in the group treated with sera from ALS patients with a mutation in the <i>chromosome 9 open reading frame 72</i> gene.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Polg&#xe1;r</LastName><ForeName>Tam&#xe1;s F</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>Biological Research Centre, Institute of Biophysics, 62 Temesv&#xe1;ri krt., 6726 Szeged, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Theoretical Medicine Doctoral School, University of Szeged, 97 Tisza Lajos krt., 6722 Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meszl&#xe9;nyi</LastName><ForeName>Val&#xe9;ria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Biological Research Centre, Institute of Biophysics, 62 Temesv&#xe1;ri krt., 6726 Szeged, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Albert Szent-Gy&#xf6;rgyi Health Centre, Department of Neurology, University of Szeged, 6 Semmelweis u., 6725 Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>N&#xf3;gr&#xe1;di</LastName><ForeName>Bern&#xe1;t</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-8643-0367</Identifier><AffiliationInfo><Affiliation>Biological Research Centre, Institute of Biophysics, 62 Temesv&#xe1;ri krt., 6726 Szeged, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Albert Szent-Gy&#xf6;rgyi Health Centre, Department of Neurology, University of Szeged, 6 Semmelweis u., 6725 Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xf6;rm&#xf6;czy</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Biological Research Centre, Institute of Biophysics, 62 Temesv&#xe1;ri krt., 6726 Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spis&#xe1;k</LastName><ForeName>Krisztina</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-0902-1046</Identifier><AffiliationInfo><Affiliation>Biological Research Centre, Institute of Biophysics, 62 Temesv&#xe1;ri krt., 6726 Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tripolszki</LastName><ForeName>Korn&#xe9;lia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Genetics, University of Szeged, 4/B Sz&#x151;kefalvi-Nagy B&#xe9;la u., 6720 Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sz&#xe9;ll</LastName><ForeName>M&#xe1;rta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Genetics, University of Szeged, 4/B Sz&#x151;kefalvi-Nagy B&#xe9;la u., 6720 Szeged, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dermatological Research Group, Hungarian Academy of Sciences, University of Szeged, 4/B Sz&#x151;kefalvi-Nagy B&#xe9;la u., 6720 Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ob&#xe1;l</LastName><ForeName>Izabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Albert Szent-Gy&#xf6;rgyi Health Centre, Department of Neurology, University of Szeged, 6 Semmelweis u., 6725 Szeged, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Aalborg University Hospital, 15 Skovvej Sdr., 9000 Aalborg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engelhardt</LastName><ForeName>J&#xf3;zsef I</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Albert Szent-Gy&#xf6;rgyi Health Centre, Department of Neurology, University of Szeged, 6 Semmelweis u., 6725 Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sikl&#xf3;s</LastName><ForeName>L&#xe1;szl&#xf3;</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Biological Research Centre, Institute of Biophysics, 62 Temesv&#xe1;ri krt., 6726 Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patai</LastName><ForeName>Roland</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-5302-2815</Identifier><AffiliationInfo><Affiliation>Biological Research Centre, Institute of Biophysics, 62 Temesv&#xe1;ri krt., 6726 Szeged, Hungary.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>GINOP-2.3.2-15-2016-00034</GrantID><Agency>Nemzetgazdas&#xe1;gi Miniszt&#xe9;rium</Agency><Country/></Grant><Grant><GrantID>FEIF/433-4/2020-ITM_SZERZ</GrantID><Agency>Innov&#xe1;ci&#xf3;s &#xe9;s Technol&#xf3;giai Miniszt&#xe9;rium</Agency><Country/></Grant><Grant><GrantID>NTP-NFT&#xd6;-21-B-0203</GrantID><Agency>Emberi Eroforr&#xe1;sok Miniszt&#xe9;riuma</Agency><Country/></Grant><Grant><GrantID>EFOP 3.6.3-VEKOP-16-2017-00009</GrantID><Agency>P&#xe9;nz&#xfc;gyminiszt&#xe9;rium</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007136">Immunoglobulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007136" MajorTopicYN="N">Immunoglobulins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C9ORF72</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">blood serum</Keyword><Keyword MajorTopicYN="N">motoneuronal calcium increase</Keyword><Keyword MajorTopicYN="N">motoneuronal loss</Keyword><Keyword MajorTopicYN="N">passive transfer</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34576165</ArticleId><ArticleId IdType="pmc">PMC8470779</ArticleId><ArticleId IdType="doi">10.3390/ijms22189994</ArticleId><ArticleId IdType="pii">ijms22189994</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O., van den Berg L.H., Kiernan M.C. Clinical Diagnosis and Management of Amyotrophic Lateral Sclerosis. Nat. Rev. Neurol. 2011;7:639&#x2013;649. doi: 10.1038/nrneurol.2011.153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.153</ArticleId><ArticleId IdType="pubmed">21989247</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B., Robberecht W. The Phenotypic Variability of Amyotrophic Lateral Sclerosis. Nat. Rev. Neurol. 2014;10:661&#x2013;670. doi: 10.1038/nrneurol.2014.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.184</ArticleId><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., van den Berg L.H., Veldink J. Gene Discovery in Amyotrophic Lateral Sclerosis: Implications for Clinical Management. Nat. Rev. Neurol. 2016;13:96&#x2013;104. doi: 10.1038/nrneurol.2016.182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.182</ArticleId><ArticleId IdType="pubmed">27982040</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha-Oliveira T., Montezinho L., Mendes C., Firuzi O., Saso L., Oliveira P.J., Silva F.S.G. Oxidative Stress in Amyotrophic Lateral Sclerosis: Pathophysiology and Opportunities for Pharmacological Intervention. Oxid. Med. Cell. Longev. 2020;2020:1&#x2013;29. doi: 10.1155/2020/5021694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/5021694</ArticleId><ArticleId IdType="pmc">PMC7683149</ArticleId><ArticleId IdType="pubmed">33274002</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Gall L., Anakor E., Connolly O., Vijayakumar U., Duddy W., Duguez S. Molecular and Cellular Mechanisms Affected in ALS. JPM. 2020;10:101. doi: 10.3390/jpm10030101.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm10030101</ArticleId><ArticleId IdType="pmc">PMC7564998</ArticleId><ArticleId IdType="pubmed">32854276</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudman J., Qi X. Stress Granule Dysregulation in Amyotrophic Lateral Sclerosis. Front. Cell. Neurosci. 2020;14:598517. doi: 10.3389/fncel.2020.598517.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2020.598517</ArticleId><ArticleId IdType="pmc">PMC7705167</ArticleId><ArticleId IdType="pubmed">33281563</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafinca R., Barbagallo P., Talbot K. The Role of Mitochondrial Dysfunction and ER Stress in TDP-43 and C9ORF72 ALS. Front. Cell. Neurosci. 2021;15:653688. doi: 10.3389/fncel.2021.653688.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.653688</ArticleId><ArticleId IdType="pmc">PMC8047135</ArticleId><ArticleId IdType="pubmed">33867942</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Appel S.H. Immune dysregulation in amyotrophic lateral sclerosis: Mechanisms and emerging therapies. Lancet Neurol. 2019;18:211&#x2013;220. doi: 10.1016/S1474-4422(18)30394-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30394-6</ArticleId><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;land L.-C., Markovinovic A., Jakovac H., de Marchi F., Bilic E., Mazzini L., Kriz J., Munitic I. Immunity in Amyotrophic Lateral Sclerosis: Blurred Lines between Excessive Inflammation and Inefficient Immune Responses. Brain Commun. 2020;2:fcaa124. doi: 10.1093/braincomms/fcaa124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa124</ArticleId><ArticleId IdType="pmc">PMC7585698</ArticleId><ArticleId IdType="pubmed">33134918</ArticleId></ArticleIdList></Reference><Reference><Citation>Tedeschi V., Petrozziello T., Secondo A. Calcium Dyshomeostasis and Lysosomal Ca2+ Dysfunction in Amyotrophic Lateral Sclerosis. Cells. 2019;8:1216. doi: 10.3390/cells8101216.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8101216</ArticleId><ArticleId IdType="pmc">PMC6829585</ArticleId><ArticleId IdType="pubmed">31597311</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapeli K., Martinez F.J., Yeo G.W. Genetic Mutations in RNA-Binding Proteins and Their Roles in ALS. Hum. Genet. 2017;136:1193&#x2013;1214. doi: 10.1007/s00439-017-1830-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00439-017-1830-7</ArticleId><ArticleId IdType="pmc">PMC5602095</ArticleId><ArticleId IdType="pubmed">28762175</ArticleId></ArticleIdList></Reference><Reference><Citation>Burk K., Pasterkamp R.J. Disrupted Neuronal Trafficking in Amyotrophic Lateral Sclerosis. Acta Neuropathol. 2019;137:859&#x2013;877. doi: 10.1007/s00401-019-01964-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-01964-7</ArticleId><ArticleId IdType="pmc">PMC6531423</ArticleId><ArticleId IdType="pubmed">30721407</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger K.A. Basic Mechanisms of Neurodegeneration: A Critical Update. J. Cell. Mol. Med. 2010;14:457&#x2013;487. doi: 10.1111/j.1582-4934.2010.01010.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2010.01010.x</ArticleId><ArticleId IdType="pmc">PMC3823450</ArticleId><ArticleId IdType="pubmed">20070435</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland L.P., Shneider N.A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2001;344:1688&#x2013;1700. doi: 10.1056/NEJM200105313442207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200105313442207</ArticleId><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland D.W., Rothstein J.D. From Charcot to Lou Gehrig: Deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci. 2001;2:806&#x2013;819. doi: 10.1038/35097565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35097565</ArticleId><ArticleId IdType="pubmed">11715057</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor J.P., Brown R.H., Jr., Cleveland D.W. Decoding ALS: From genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Sikl&#xf3;s L., Engelhardt J., Harati Y., Smith R.G., Jo&#xf3; F., Appel S.H. Ultrastructural evidence for altered calcium in motor nerve terminals in amyotrophic lateral sclerosis. Ann. Neurol. 1996;39:203&#x2013;216. doi: 10.1002/ana.410390210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410390210</ArticleId><ArticleId IdType="pubmed">8967752</ArticleId></ArticleIdList></Reference><Reference><Citation>Sikl&#xf3;s L., Engelhardt J.I., Alexianu M.E., Gurney M.E., Siddique T., Appel S.H. Intracellular calcium parallels motoneuron degeneration in SOD-1 mutant mice. J. Neuropathol. Exp. Neurol. 1998;57:571&#x2013;587. doi: 10.1097/00005072-199806000-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199806000-00005</ArticleId><ArticleId IdType="pubmed">9630237</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt J.I., Sikl&#xf3;s L., K&#xf6;m&#xfc;ves L., Smith R.G., Appel S.H. Antibodies to calcium channels from ALS patients passively transferred to mice selectively increase intracellular calcium and induce ultrastructural changes in motoneurons. Synapse. 1995;20:185&#x2013;199. doi: 10.1002/syn.890200302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/syn.890200302</ArticleId><ArticleId IdType="pubmed">7570350</ArticleId></ArticleIdList></Reference><Reference><Citation>Ob&#xe1;l I., N&#xf3;gr&#xe1;di B., Meszl&#xe9;nyi V., Patai R., Ricken G., Kovacs G.G., Tripolszki K., Sz&#xe9;ll M., Sikl&#xf3;s L., Engelhardt J.I. Experimental Motor Neuron Disease Induced in Mice with Long-Term Repeated Intraperitoneal Injections of Serum from ALS Patients. Int. J. Mol. Sci. 2019;20:2573. doi: 10.3390/ijms20102573.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20102573</ArticleId><ArticleId IdType="pmc">PMC6566871</ArticleId><ArticleId IdType="pubmed">31130623</ArticleId></ArticleIdList></Reference><Reference><Citation>Meszl&#xe9;nyi V., Patai R., Polg&#xe1;r T.F., N&#xf3;gr&#xe1;di B., K&#xf6;rm&#xf6;czy L., Krist&#xf3;f R., Spis&#xe1;k K., Tripolszki K., Sz&#xe9;ll M., Ob&#xe1;l I., et al. Passive Transfer of Sera from ALS Patients with Identified Mutations Evokes an Increased Synaptic Vesicle Number and Elevation of Calcium Levels in Motor Axon Terminals, Similar to Sera from Sporadic Patients. Int. J. Mol. Sci. 2020;21:5566. doi: 10.3390/ijms21155566.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21155566</ArticleId><ArticleId IdType="pmc">PMC7432249</ArticleId><ArticleId IdType="pubmed">32756522</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt J.I., Siklos L., Appel S.H. Altered calcium homeostasis and ultrastructure in motoneurons of mice caused by passively transferred anti-motoneuronal IgG. J. Neuropathol. Exp. Neur. 1997;56:21&#x2013;39. doi: 10.1097/00005072-199701000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199701000-00003</ArticleId><ArticleId IdType="pubmed">8990126</ArticleId></ArticleIdList></Reference><Reference><Citation>Patai R., N&#xf3;gr&#xe1;di B., Engelhardt J.I., Sikl&#xf3;s L. Calcium in the pathomechanism of amyotrophic lateral sclerosis&#x2014;Taking center stage? Biochem. Biophys. Res. Commun. 2017;483:1031&#x2013;1039. doi: 10.1016/j.bbrc.2016.08.089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2016.08.089</ArticleId><ArticleId IdType="pubmed">27545602</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfgram F., Myers L. Amyotrophic Lateral Sclerosis: Effect of Serum on Anterior Horn Cells in Tissue Culture. Science. 1973;179:579&#x2013;580. doi: 10.1126/science.179.4073.579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.179.4073.579</ArticleId><ArticleId IdType="pubmed">4119685</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng Kee Kwong K.C., Harbham P.K., Selvaraj B.T., Gregory J.M., Pal S., Hardingham G.E., Chandran S., Mehta A.R. 40 Years of CSF Toxicity Studies in ALS: What Have We Learnt About ALS Pathophysiology? Front. Mol. Neurosci. 2021;14:647895. doi: 10.3389/fnmol.2021.647895.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2021.647895</ArticleId><ArticleId IdType="pmc">PMC8012723</ArticleId><ArticleId IdType="pubmed">33815058</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S., Nalini A., Laxmi T.R., Raju T.R. ALS-CSF-induced structural changes in spinal motor neurons of rat pups cause deficits in motor behaviour. Exp. Brain Res. 2021;239:315&#x2013;327. doi: 10.1007/s00221-020-05969-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00221-020-05969-7</ArticleId><ArticleId IdType="pubmed">33170340</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R.G., Hamilton S., Hofmann F., Schneider T., Nastainczyk W., Birnbaumer L., Stefani E., Appel S.H. Serum antibodies to L-type calcium channels in patients with amyotrophic lateral sclerosis. N. Engl. J. Med. 1992;327:1721&#x2013;1728. doi: 10.1056/NEJM199212103272405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199212103272405</ArticleId><ArticleId IdType="pubmed">1331790</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt J.I., Appel S.H. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch. Neurol. 1990;47:1210&#x2013;1216. doi: 10.1001/archneur.1990.00530110068019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1990.00530110068019</ArticleId><ArticleId IdType="pubmed">2122877</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexianu M.E., Mohamed A.H., Smith R.G., Colom L.V., Appel S.H. Apoptotic cell death of a hybrid motoneuron cell line induced by immunoglobulins from patients with amyotrophic lateral sclerosis. J. Neurochem. 1994;63:2365&#x2013;2368. doi: 10.1046/j.1471-4159.1994.63062365.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1994.63062365.x</ArticleId><ArticleId IdType="pubmed">7964760</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosier D.R., Baldelli P., Delbono O., Smith R.G., Alexianu M.E., Appel S.H., Stefani E. Amyotrophic lateral sclerosis immunoglobulins increase Ca2+ currents in a motoneuron cell line. Ann. Neurol. 1995;37:102&#x2013;109. doi: 10.1002/ana.410370119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410370119</ArticleId><ArticleId IdType="pubmed">7818241</ArticleId></ArticleIdList></Reference><Reference><Citation>Colom L.V., Alexianu M.E., Mosier D.R., Smith R.G., Appel S.H. Amyotrophic lateral sclerosis immunoglobulins increase intracellular calcium in a motoneuron cell line. Exp. Neurol. 1997;146:354&#x2013;360. doi: 10.1006/exnr.1997.6541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.1997.6541</ArticleId><ArticleId IdType="pubmed">9270044</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues M.C., Hernandez-Ontiveros D.G., Louis M.K., Willing A.E., Borlongan C.V., Sanberg P.R., Voltarelli J.C., Garbuzova-Davis S. Neurovascular aspects of amyotrophic lateral sclerosis. Int. Rev. Neurobiol. 2012;102:91&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">22748827</ArticleId></ArticleIdList></Reference><Reference><Citation>Bataveljic D., Milosevic M., Radenovic L., Andjus P. Novel molecular biomarkers at the blood-brain barrier in ALS. Biomed. Res. Int. 2014;2014:907545. doi: 10.1155/2014/907545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/907545</ArticleId><ArticleId IdType="pmc">PMC4037612</ArticleId><ArticleId IdType="pubmed">24949481</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer A.M. The role of the blood brain barrier in neurodegenerative disorders and their treatment. J. Alzheimer&#x2019;s Dis. 2011;24:643&#x2013;656. doi: 10.3233/JAD-2011-110368.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-110368</ArticleId><ArticleId IdType="pubmed">21460432</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar N.N., Pizzo M.E., Nehra G., Wilken-Resman B., Boroumand S., Thorne R.G. Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches. Bioconjug. Chem. 2018;29:3937&#x2013;3966. doi: 10.1021/acs.bioconjchem.8b00548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.bioconjchem.8b00548</ArticleId><ArticleId IdType="pmc">PMC7234797</ArticleId><ArticleId IdType="pubmed">30265523</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S., Saporta S., Haller E., Kolomey I., Bennett S.P., Potter H., Sanberg P.R. Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS ONE. 2007;2:e1205. doi: 10.1371/journal.pone.0001205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0001205</ArticleId><ArticleId IdType="pmc">PMC2075163</ArticleId><ArticleId IdType="pubmed">18030339</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z., Deane R., Ali Z., Parisi M., Shapovalov Y., O&#x2019;Banion M.K., Stojanovic K., Sagare A., Boillee S., Cleveland D.W., et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat. Neurosci. 2008;11:420&#x2013;422. doi: 10.1038/nn2073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn2073</ArticleId><ArticleId IdType="pmc">PMC2895310</ArticleId><ArticleId IdType="pubmed">18344992</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicaise C., Mitrecic D., Demetter P., de Decker R., Authelet M., Boom A., Pochet R. Impaired blood-brain and blood-spinal cord barriers in mutant SOD1-linked ALS rat. Brain Res. 2009;1301:152&#x2013;162. doi: 10.1016/j.brainres.2009.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2009.09.018</ArticleId><ArticleId IdType="pubmed">19748495</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S., Hernandez-Ontiveros D.G., Rodrigues M.C., Haller E., Frisina-Deyo A., Mirtyl S., Sallot S., Saporta S., Borlongan C.V., Sanberg P.R. Impaired blood-brain/spinal cord barrier in ALS patients. Brain Res. 2012;1469:114&#x2013;128. doi: 10.1016/j.brainres.2012.05.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2012.05.056</ArticleId><ArticleId IdType="pubmed">22750125</ArticleId></ArticleIdList></Reference><Reference><Citation>Passaro A.P., Lebos A.L., Yao Y., Stice S.L. Immune Response in Neurological Pathology: Emerging Role of Central and Peripheral Immune Crosstalk. Front. Immunol. 2021;12:676621. doi: 10.3389/fimmu.2021.676621.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.676621</ArticleId><ArticleId IdType="pmc">PMC8222736</ArticleId><ArticleId IdType="pubmed">34177918</ArticleId></ArticleIdList></Reference><Reference><Citation>May C., Nordhoff E., Casjens S., Turewicz M., Eisenacher M., Gold R., Br&#xfc;ning T., Pesch B., Stephan C., Woitalla D., et al. Highly immunoreactive IgG antibodies directed against a set of twenty human proteins in the sera of patients with amyotrophic lateral sclerosis identified by protein array. PLoS ONE. 2014;9:e89596. doi: 10.1371/journal.pone.0089596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0089596</ArticleId><ArticleId IdType="pmc">PMC3935926</ArticleId><ArticleId IdType="pubmed">24586901</ArticleId></ArticleIdList></Reference><Reference><Citation>Pullen A.H., Humphreys P. Ultrastructural analysis of spinal motoneurones from mice treated with IgG from ALS patients, healthy individuals, or disease controls. J. Neurol. Sci. 2000;180:35&#x2013;45. doi: 10.1016/S0022-510X(00)00427-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(00)00427-5</ArticleId><ArticleId IdType="pubmed">11090862</ArticleId></ArticleIdList></Reference><Reference><Citation>Pullen A.H., Demestre M., Howard R.S., Orrell R.W. Passive transfer of purified IgG from patients with amyotrophic lateral sclerosis to mice results in degeneration of motor neurons accompanied by Ca2+ enhancement. Acta Neuropathol. 2004;107:35&#x2013;46. doi: 10.1007/s00401-003-0777-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-003-0777-z</ArticleId><ArticleId IdType="pubmed">14551798</ArticleId></ArticleIdList></Reference><Reference><Citation>Milo&#x161;evi&#x107; M., Mili&#x107;evi&#x107; K., Bo&#x17e;i&#x107; I., Lavrnja I., Stevanovi&#x107; I., Bijeli&#x107; D., Dubai&#x107; M., &#x17d;ivkovi&#x107; I., Stevi&#x107; Z., Giniatullin R., et al. Immunoglobulins G from Sera of Amyotrophic Lateral Sclerosis Patients Induce Oxidative Stress and Upregulation of Antioxidative System in BV-2 Microglial Cell Line. Front. Immunol. 2017;8:1619. doi: 10.3389/fimmu.2017.01619.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01619</ArticleId><ArticleId IdType="pmc">PMC5703705</ArticleId><ArticleId IdType="pubmed">29218049</ArticleId></ArticleIdList></Reference><Reference><Citation>Delbono O., Garc&#xed;a J., Appel S.H., Stefani E. IgG from amyotrophic lateral sclerosis affects tubular calcium channels of skeletal muscle. J. Physiol. 1991;260:C1347&#x2013;C1351. doi: 10.1152/ajpcell.1991.260.6.C1347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.1991.260.6.C1347</ArticleId><ArticleId IdType="pubmed">1647668</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnelli V., Sawada T., Delbono O., Smith R.G., Appel S.H., Stefani E. The action of amyotrophic lateral sclerosis immunoglobulins on mammalian single skeletal muscle Ca2+ channels. J. Physiol. 1993;461:103&#x2013;118. doi: 10.1113/jphysiol.1993.sp019504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.1993.sp019504</ArticleId><ArticleId IdType="pmc">PMC1175248</ArticleId><ArticleId IdType="pubmed">8394422</ArticleId></ArticleIdList></Reference><Reference><Citation>Llin&#xe1;s R., Sugimori M., Cherksey B.D., Smith R.G., Delbono O., Stefani E., Appel S. IgG from amyotrophic lateral sclerosis patients increases current through P-type calcium channels in mammalian cerebellar Purkinje cells and in isolated channel protein in lipid bilayer. Proc. Natl. Acad. Sci. USA. 1993;90:11743&#x2013;11747. doi: 10.1073/pnas.90.24.11743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.24.11743</ArticleId><ArticleId IdType="pmc">PMC48060</ArticleId><ArticleId IdType="pubmed">8265620</ArticleId></ArticleIdList></Reference><Reference><Citation>Ob&#xe1;l I., Klausz G., M&#xe1;ndi Y., Deli M., Sikl&#xf3;s L., Engelhardt J.I. Intraperitoneally administered IgG from patients with amyotrophic lateral sclerosis or from an immune-mediated goat model increase the levels of TNF-&#x3b1;, IL-6, and IL-10 in the spinal cord and serum of mice. J. Neuroinflamm. 2016;13:121. doi: 10.1186/s12974-016-0586-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0586-7</ArticleId><ArticleId IdType="pmc">PMC4879728</ArticleId><ArticleId IdType="pubmed">27220674</ArticleId></ArticleIdList></Reference><Reference><Citation>Nijssen J., Comley L.H., Hedlund E. Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis. Acta Neuropathol. 2017;133:863&#x2013;885. doi: 10.1007/s00401-017-1708-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1708-8</ArticleId><ArticleId IdType="pmc">PMC5427160</ArticleId><ArticleId IdType="pubmed">28409282</ArticleId></ArticleIdList></Reference><Reference><Citation>Paizs M., Patai R., Engelhardt J.I., Katarova Z., Obal I., Siklos L. Axotomy Leads to Reduced Calcium Increase and Earlier Termination of CCL2 Release in Spinal Motoneurons with Upregulated Parvalbumin Followed by Decreased Neighboring Microglial Activation. CNS Neurol. Disord. Drug Targets. 2017;16:356&#x2013;367. doi: 10.2174/1871527315666161223130409.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527315666161223130409</ArticleId><ArticleId IdType="pubmed">28017131</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Ho B.K., Sikl&#xf3;s L., Alexianu M.E., Mosier D.R., Mohamed A.H., Otsuka Y., Kozovska M.E., McAlhany R.E., Smith R.G., et al. Parvalbumin overexpression alters immune-mediated increases in intracellular calcium, and delays disease onset in a transgenic model of familial amyotrophic lateral sclerosis. J. Neurochem. 2001;79:499&#x2013;509. doi: 10.1046/j.1471-4159.2001.00582.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2001.00582.x</ArticleId><ArticleId IdType="pubmed">11701753</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W.L., George K.J., Ibba V., Liu M.C., Averill S., Quartu M., Hamlyn P.J., Priestley J.V. The characteristics of neuronal injury in a static compression model of spinal cord injury in adult rats. Eur. J. Neurosci. 2007;25:362&#x2013;372. doi: 10.1111/j.1460-9568.2006.05284.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2006.05284.x</ArticleId><ArticleId IdType="pubmed">17284176</ArticleId></ArticleIdList></Reference><Reference><Citation>Dusart I., Schwab M.E. Secondary cell death and the inflammatory reaction after dorsal hemisection of the rat spinal cord. Eur. J. Neurosci. 1994;6:712&#x2013;724. doi: 10.1111/j.1460-9568.1994.tb00983.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.1994.tb00983.x</ArticleId><ArticleId IdType="pubmed">8075816</ArticleId></ArticleIdList></Reference><Reference><Citation>Eidelberg E., Nguyen L.H., Polich R., Walden J.G. Transsynaptic degeneration of motoneurones caudal to spinal cord lesions. Brain Res. Bull. 1989;22:39&#x2013;45. doi: 10.1016/0361-9230(89)90125-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0361-9230(89)90125-1</ArticleId><ArticleId IdType="pubmed">2713715</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman S.D., Rosenberg L.J., Wrathall J.R. Temporal-spatial pattern of acute neuronal and glial loss after spinal cord contusion. Exp. Neurol. 2001;168:273&#x2013;282. doi: 10.1006/exnr.2001.7628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.2001.7628</ArticleId><ArticleId IdType="pubmed">11259115</ArticleId></ArticleIdList></Reference><Reference><Citation>Fifield K.E., Vanderluit J.L. Rapid degeneration of neurons in the penumbra region following a small, focal ischemic stroke. Eur. J. Neurosci. 2020;52:3196&#x2013;3214. doi: 10.1111/ejn.14678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejn.14678</ArticleId><ArticleId IdType="pubmed">31945213</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R., Isaacs A.M. C9orf72-mediated ALS and FTD: Multiple pathways to disease. Nat. Rev. Neurol. 2018;14:544&#x2013;558. doi: 10.1038/s41582-018-0047-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0047-2</ArticleId><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Lall D., Baloh R.H. Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia. J. Clin. Investig. 2017;127:3250&#x2013;3258. doi: 10.1172/JCI90607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI90607</ArticleId><ArticleId IdType="pmc">PMC5669558</ArticleId><ArticleId IdType="pubmed">28737506</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudria-Lopez E., Koppers M., de Wit M., van der Meer C., Westeneng H.J., Zundel C.A., Youssef S.A., Harkema L., de Bruin A., Veldink J.H. Full ablation of C9orf72 in mice causes immune system-related pathology and neoplastic events but no motor neuron defects. Acta Neuropathol. 2016;132:145&#x2013;147. doi: 10.1007/s00401-016-1581-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1581-x</ArticleId><ArticleId IdType="pmc">PMC4911370</ArticleId><ArticleId IdType="pubmed">27206760</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong J., Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J. Neurosci. 1998;18:3241&#x2013;3250. doi: 10.1523/JNEUROSCI.18-09-03241.1998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.18-09-03241.1998</ArticleId><ArticleId IdType="pmc">PMC6792665</ArticleId><ArticleId IdType="pubmed">9547233</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>